Mobility Direct Releases Comprehensive State-by-State Research Resource Examining Mobility Scooter Regulations, Accessibility Rules, and Public Guidance Across the United StatesDEERFIELD BEACH, Fla., June 2,...
Holistic engagement programs offer healthcare organizations a scalable solution to support women and families in managing their physical, mental, and emotional health.
ASBURY PARK, N.J.,...
PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...
Funding will support behavioral health crisis services at Nationwide Children's Hospital and provide free educational resources through The Kids Mental Health Foundation.
COLUMBUS, Ohio, Aug....
Class Actions Seeks to Represent Untold Number of Caregivers Who Appealed Denials from the VA's Program of Comprehensive Assistance for Family Caregivers
WASHINGTON, Aug. 12,...
The ADAPT study will evaluate the safety and effectiveness of the company's Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System
CAMPBELL, Calif., Aug. 12, 2025 /PRNewswire/...
NAPLES, Fla., Aug. 11, 2025 /PRNewswire/ -- Prisidio, the secure digital vault company that helps individuals and families Collect, Protect, and Share their most essential...
Nurse Practitioners, Physician Assistants, and Certified Nurse Midwives at Cape Cod Healthcare move to join the MNA for an equal voice in clinical decisions
CAPE...
Dr. Wenham is Principal investigator on Anixa's CAR-T therapy for Ovarian Cancer
SAN JOSE, Calif., Aug. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or...
ATLANTA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three and six-month periods ended June 28, 2025.
MARKHAM, Ontario, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and six months ended June 30, 2025.
CORAL GABLES, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer (SCLC) now include new additions involving Lambert Eaton myasthenic syndrome (LEMS), amifampridine (FIRDAPSE®), and the tests for PQ- and N-type voltage-gated calcium channel (VGCC) antibodies.